PRE PRENETICS GLOBAL LIMITED

Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University

CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  , the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class (SAB). These additions underscore IM8’s unwavering commitment to leading innovation in science, longevity and human performance.

Newly joining IM8’s SAB are:

Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on gut health, hormonal balance and nutrition. Her practical, evidence-based approach and extensive experience in integrative wellness will guide IM8’s continued development of comprehensive wellness solutions.

Dr. Jeremy London – With over 25 years of experience, Dr. London is a board-certified and renowned cardiothoracic surgeon specializing in preventive cardiovascular health. He is recognized as a leader in minimally invasive heart valve treatments and thoracic aortic aneurysm repair. Dr. London’s deep commitment to preventive care and patient education will further enhance IM8’s cardiovascular health product initiatives.

“Our Scientific Advisory Board has been instrumental since day one in helping us set industry-leading standards," said Danny Yeung, co-founding partner and CEO of IM8. “We’re eager to welcome Dr. Jeremy London and Dr. Amy Shah, whose exceptional expertise will elevate our innovative research and product development even further, reinforcing IM8’s position as a trusted leader in health and wellness.”

Since its inception, IM8’s SAB has featured top experts whose contributions have been crucial to the company’s product development. Among those experts include:

Dr. Dawn Mussallem – Integrative Oncologist at Mayo Clinic

Dr. Mussallem is a distinguished consultant in the Division of Hematology Oncology at Mayo Clinic, where she has served as a clinician for over 20 years, and an Assistant Professor of Medicine. She is a double board-certified lifestyle medicine breast specialist at The Robert and Monica Jacoby Center for Breast Health and founded the Integrative Medicine and Breast Health Program at Mayo Clinic Florida.

Dr. Jim Green – Former Chief Scientist of NASA

Dr. Green has led numerous groundbreaking NASA missions, including Mars Rover landings and the New Horizons mission to Pluto. His expertise in space science and biomedical innovations uniquely benefits IM8’s approach to health and longevity.

Dr. James DiNicolantonio – Cardiovascular Research Scientist and Author

Dr. DiNicolantonio is widely recognized for his research on nutrition, metabolism and human health. He is known for translating complex nutritional science into actionable health advice, strengthening IM8’s nutritional offerings. He is the author/co-author of over 250 academic publications in the medical literature spanning nutrition, nutraceuticals, cardiovascular health, longevity and overall health.

Dr. Suzanne Devkota – Director of Microbiome Research Lab at Cedars-Sinai Medical Center

Dr. Devkota’s pioneering research in microbiome science and its role in chronic diseases aligns closely with IM8’s commitment to developing innovative gut-health solutions. With over 15 years of experience in the field, Dr. Devkota’s research emphasizes the critical connection between the microbiome and overall health, highlighting the potential for microbiome-based therapies.

Dr. David Katz – Founding Director of Yale-Griffin Prevention Research Center

Dr. Katz is an internationally recognized expert in preventive medicine, nutrition and public health. His contributions have significantly influenced IM8’s scientifically-validated nutrition and preventive healthcare solutions. He has roughly 250 peer-reviewed publications and has authored/co-authored 19 books to date including multiple editions of leading textbooks in nutrition, preventive medicine, and epidemiology.

Dr. Stephen Anton – Professor in the Department of Physiology and Aging at University of Florida

Prof. Stephen Anton is a renowned expert in aging and metabolic health, with over 20 years of experience in the field. He is a Distinguished Professor at the University of Florida with a primary appointment in the Department of Physiology and Aging. Prof. Anton’s research focuses on the interplay between lifestyle factors, metabolic health, and aging, with a particular emphasis on the benefits of caloric restriction, intermittent fasting, and physical activity.

IM8’s flagship product, , exemplifies the SAB’s foundational role. This clinically-validated all-in-one daily powder supplement is designed to replace up to 16 supplements, enhancing energy, immunity, digestion and longevity. Supported by rigorous clinical trials and third-party NSF certification for Sport, it demonstrates IM8’s dedication to quality, transparency and efficacy.

The global supplements market is valued at by 2028, driven by growing consumer demand for credible, scientifically-backed products.

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics, a leading global health sciences company dedicated to advancing consumer health.

Media Contact

Camille Livesay

Jack Taylor Public Relations



EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PRENETICS GLOBAL LIMITED

 PRESS RELEASE

Prenetics Announces Upcoming Conference Participation

Prenetics Announces Upcoming Conference Participation CHARLOTTE, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced its participation in the following upcoming investor conferences. The Company will participate in The Benchmark Company’s 14th Annual Discovery One-on-One Conference, taking place December 4, 2025, at the New York Athletic Club in New York City. Prenetics Chief Executive Officer Danny Yeung will be available ...

 PRESS RELEASE

Prenetics Executives Announce Open Market Share Purchases Totaling App...

Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8 and a global health-tech and longevity company pioneering a dual-engine strategy across consumer wellness and Bitcoin, today announced that all key members of its executive leadership team have executed open market purchases of Prenetics’ common stock during the Company’s designated trading window. In total, the executive team acquired 111,911 shares of P...

 PRESS RELEASE

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price...

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company’s Financial Position Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent...

 PRESS RELEASE

Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for ...

Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLO...

 PRESS RELEASE

Prenetics Announces Third Quarter 2025 Financial Results Release Date ...

Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch